The drug, which treats brain cancers including glioblastoma, does not have a generic alternative and can cost as much as $1,000 per capsule, the article said.
In a statement to the Journal, NextSource said it is exploring a new contract with the program and plans to participate again in the future, though it did not specify why the drug’s coverage benefits ended Jan. 1.
NextSource also told the publication that Medicare patients meeting certain income criteria have been eligible to receive the drug at no cost since January.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.